## MRK: Merck & Co., Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.12 indicates fundamental undervaluation. Quality metrics strong (ROE 40%, ROA 14%). Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-7.1% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($94.28)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 1)

**1. FDA Conditionally Approves Merck Animal Health's EXZOLT™ CATTLE-CA1 for the Prevention and Treatment of New World Screwworm (Cochliomyia hominivorax) Larvae (myiasis)**
- Source: Business Wire | 20251205T071025 | Bullish | Relevance: 100%
- Merck Animal Health announced that the FDA has granted conditional approval for EXZOLT™ CATTLE-CA1 (fluralaner topical solution), an innovative product in the isoxazoline class of parasiticides. This pour-on solution is effective for the prevention and treatment of New World screwworm larvae and is also conditionally approved for the treatment and control of cattle fever tick. This approval provides a new tool for veterinarians and cattle producers to protect livestock, safeguarding the industry's economic future and the nation’s beef supply.

**2. FDA Conditionally Approves Merck Animal Health's EXZOLT™ CATTLE-CA1 for the Prevention and Treatment of New World Screwworm (Cochliomyia hominivorax) Larvae (myiasis)**
- Source: PharmiWeb.com | 20251204T201330 | Bullish | Relevance: 100%
- The FDA has granted conditional approval to Merck Animal Health's EXZOLT™ CATTLE-CA1 (fluralaner topical solution) for the prevention and treatment of New World screwworm and treatment and control of cattle fever tick. This is the first ectoparasiticide for beef cattle in decades and allows veterinarians and cattle producers a new tool to protect livestock from these parasites. EXZOLT™ CATTLE-CA1 is approved for beef cattle two months and older and replacement dairy heifers under 20 months, with a 98-day meat withdrawal period.

**3. Merck (NYSE: MRK) gets FDA conditional OK for EXZOLT CATTLE-CA1 vs New World screwworm**
- Source: Stock Titan | 20251204T170807 | Bullish | Relevance: 100%
- Merck Animal Health has received conditional FDA approval for EXZOLT™ CATTLE-CA1, an innovative pour-on solution for cattle. This marks the first isoxazoline parasiticide conditionally approved for the prevention and treatment of New World screwworm larvae and control of cattle fever ticks. The product addresses a significant threat to U.S. agriculture and will be available by prescription in early 2026.

**4. Merck & Co., Inc. at the Citi 2025 Global Healthcare Conference**
- Source: Merck.com | 20251203T130000 | Neutral | Relevance: 100%
- Merck & Co., Inc. announced its participation in the Citi 2025 Global Healthcare Conference, scheduled for December 3, 2025, at 1:00 p.m. EST. The company provides details for adding the event to various calendars and contact information for investor inquiries. Key investor resources, including financial information, stock data, and investor services, are also highlighted.

**5. Trek Financial LLC Decreases Stock Holdings in Merck & Co., Inc. $MRK**
- Source: MarketBeat | 20251205T134342 | Somewhat-Bullish | Relevance: 100%
- Trek Financial LLC significantly reduced its stake in Merck & Co., Inc. by 62.3% in Q2, selling 11,161 shares and retaining 6,768 shares valued at $536,000. This comes as Merck reported strong Q2 earnings, beating estimates, setting robust FY2025 guidance, and increasing its quarterly dividend. Analyst opinions on Merck are mixed, with some upgrading to "buy" while the consensus remains "hold," indicating varied perspectives on its future performance despite the positive financial results.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-04 | Scotiabank | $120 | $105 | +14% |
| 2025-12-02 | Goldman Sachs | $120 | $92 | +30% |
| 2025-11-24 | Wells Fargo | $125 | $90 | +39% |
| 2025-11-18 | Deutsche Bank | $111 | $110 | +1% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-04 | Scotiabank | main | Sector Outperform |
| 2025-12-02 | Goldman Sachs | main | Buy |
| 2025-11-24 | Wells Fargo | up | Overweight |
| 2025-11-18 | Deutsche Bank | main | Hold |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($0.09M) |
| Sells | 2 ($1.34M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.2% (-0.3%)
- Blackrock Inc.: 8.7% (-1.6%)
- State Street Corpora: 4.8% (-0.3%)
- Wellington Managemen: 3.0% (-2.0%)
- JPMORGAN CHASE & CO: 2.8% (+121.2%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-7.1% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 4 raises (avg +21%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.12 suggests fair value with growth premium. Quality metrics strong (ROE 40%, ROA 14%, margin 30%). Balance sheet: $6.8B free cash flow. Analyst sentiment positive (4 raises, avg +21%). Insider selling cluster ($1.3M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $266.7B |
| Beta | 0.30 |
| 52W Range | $73.31 - $107.04 |
| Short Interest | 1.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.12 |
| Forward P/E | 12.0 |
| Current P/E | 11.1 |
| YoY Growth | -7.6% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 7.6% to 0.5% (-7.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.5pp (needs >4.0% for momentum thesis). MRS_5 (-2.0%) diverging from MRS_20 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.49% (CS: 58) | Neutral |
| RSI_14 | 60.2 | Neutral |
| MACD Histogram | -0.06 | Bearish |
| vs SMA20 | 1.028x | Above |
| vs SMA50 | 1.104x | Above |
| vs SMA200 | 1.176x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $99.72
- **Stop Loss:** $94.28 (5.5% risk)
- **Target:** $110.60 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 91
- **Position Value:** $9,074.52
- **Portfolio %:** 9.07%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-02-03 (Est: $2.05)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.35 | $2.58 | +9.9% |
| 2025Q2 | $2.03 | $2.13 | +5.0% |
| 2025Q1 | $2.14 | $2.22 | +4.0% |
| 2024Q4 | $1.67 | $1.72 | +3.3% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*